Both trials will assess the safety and efficacy of APL-2 in patients with GA, an advanced form of age-related macular degeneration. There are …



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *